[Skip to Navigation]
March 27, 2020

A Novel Cardioprotective Therapy That Also Improves Glycemia

Author Affiliations
  • 1The George Institute for Global Health, UNSW Sydney, Sydney, Australia
  • 2Imperial College London, London, England
  • 3Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, UNSW Sydney
JAMA. 2020;323(14):1349-1350. doi:10.1001/jama.2020.1905

The profound effects of sodium-glucose transporter 2 (SGLT2) inhibition on the risks of cardiovascular complications in patients with hyperglycemia have provided for rapid and substantive changes to diabetes guidelines from various countries. In this issue of JAMA, Petrie and colleagues1 report findings from a highly informative exploratory analysis of the most recent large-scale clinical trial of an SGLT2 inhibitor that may suggest the next chapter for this drug class—the transition from a glucose-lowering therapy that provides cardioprotection to a cardioprotective agent that happens to lower blood glucose.